Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 28;61(4):622.
doi: 10.3390/medicina61040622.

Evaluation of the Efficacy of Active Hexose Correlated Compound as an Adjuvant in Reducing Recurrence After Condyloma Cauterization

Ufuk Atlihan  1 , Onur Yavuz  2 , Can Ata  3 , Huseyin Aytug Avsar  4 , Tevfik Berk Bildaci  5 , Ali Cenk Ozay  6 , Burak Ersak  7 , Ulas Solmaz  8 , Selcuk Erkilinc  9
Affiliations

Evaluation of the Efficacy of Active Hexose Correlated Compound as an Adjuvant in Reducing Recurrence After Condyloma Cauterization

Ufuk Atlihan et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Human papillomavirus (HPV) is one of the most prevalent sexually transmitted illnesses. HPV is responsible for genital condyloma lesions. A durable and effective systemic treatment regimen has not been established for HPV-related infections. In the present study, our purpose was to evaluate the role of active hexose correlated compound (AHCC) in preventing relapse in patients who underwent cauterization for condyloma accuminata. Materials and Methods: A total of 244 individuals admitted to our hospital between January 2019 and June 2022 were diagnosed as having condyloma acuminata, and those who underwent condyloma cauterization were evaluated retrospectively. We included 133 individuals who met the criteria. Patients who received AHCC were scheduled for follow-up examinations at regular intervals every three months. Patients were divided into two groups and analyzed based on whether they did or did not use AHCC. Results: The average age of AHCC non-users was significantly greater than that of AHCC users (p < 0.01). The number of condylomas and the maximum condyloma diameter of AHCC users before treatment were found to be significantly higher than in AHCC non-users (p = 0.006 and p = 0.004, respectively). Among participants with recurrence, the number and diameter of condylomas in AHCC users were significantly lower than in AHCC non-users (p = 0.019 and p = 0.042, respectively). Conclusions: Although the usage of AHCC is not expected to help prevent recurrence after the cauterization of condylomata acuminate in all patients, physicians may consider AHCC as a nutritional supplement and supportive therapy in the absence of other systemic treatments. Consequently, the duration of AHCC support necessary to optimize the effect of AHCC use on relapse prevention requires further evaluation on the basis of both target IFN-β levels and HPV infection status.

Keywords: active hexose correlated compound; condylomata acuminate; human papillomavirus; relapse.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Furumoto H., Irahara M. Human papilloma virus (HPV) and cervical cancer. J. Med. Investig. 2002;49:124–133. - PubMed
    1. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 2006;110:525–541. doi: 10.1042/CS20050369. - DOI - PubMed
    1. Gunter J. Genital and perianal warts: New treatment opportunities for human papillomavirus infection. Am. J. Obstet. Gynecol. 2003;189:S3–S11. - PubMed
    1. Thompson A.B., Flowers L.C. Sexually Transmitted Infections in Adolescence and Young Adulthood: A Practical Guide for Clinicians. Springer; Cham, Switzerland: 2020. Human papillomavirus (HPV) pp. 279–297.
    1. Chan P.K., Chang A.R., Yu M.Y., Li W.H., Chan M.Y., Yeung A.C., Cheung T.H., Yau T.N., Wong S.M., Yau C.W., et al. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. Int. J. Cancer. 2010;126:297–301. doi: 10.1002/ijc.24731. - DOI - PubMed

Substances

LinkOut - more resources